Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)

Bio2RDF identifier

NCT00543543

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00543543

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00543543

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

14.840

http://www.w3.org/2001/XMLSchema#integer

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... odies compared with GARDASIL.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Broad Spectrum HPV (Human Papi ...... o 26-Year-Old Women (V503-001)

http://www.w3.org/2001/XMLSchema#string

clinical result [clinicaltrials_vocabulary:clinical-result]

clinical results for clinicaltrials:NCT00543543 [clinicaltrials_resource:228ae83c4d600fa8d20407b5878b5507]

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) From Day 1 until >=30 cases accumulate, up to Month 54 in the base study [clinicaltrials_resource:28b4561723d4b85fa36e6bcf4f579f91]

Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) From Day 1 until >=30 cases accumulate, up to Month 54 in the base study [clinicaltrials_resource:44e01687a7041c0568fb94e1095624f8]

Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) From Day 1 until >=30 cases accumulate, up to Month 54 in the base study [clinicaltrials_resource:4eee463977ba145322ba3778c59a9a80]

Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) From Day 1 until >=30 cases accumulate, up to Month 54 in the base study [clinicaltrials_resource:663c4a050151ae0c5120939a9e1487b4]

Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) From Day 1 until >=30 cases accumulate, up to Month 54 in the base study [clinicaltrials_resource:7f91f7543de78a2f71bbb6b4c4e79ff3]

Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) From Day 1 until >=30 cases accumulate, up to Month 54 in the base study [clinicaltrials_resource:c58882cc829a7a5ae10930c337b5d270]

Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) From Day 1 until >=30 cases accumulate, up to Month 54 in the base study [clinicaltrials_resource:d143dfa1591fc0cfd5675a52b2392ee0]

Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) From Day 1 until >=30 cases accumulate, up to Month 54 in the base study [clinicaltrials_resource:ecaeb5e2df41f995769988dca78621fd]

Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) From Day 1 until >=30 cases accumulate, up to Month 54 in the base study [clinicaltrials_resource:fde837d1910f9bac05907764ea3a8f70]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) From Day 1 until >=30 cases accumulate, up to Month 54 in the base study [clinicaltrials_resource:aef5c0583e038a296e3142517167e591]

Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) From Day 1 until >=30 cases accumulate, up to Month 54 in the base study [clinicaltrials_resource:ce3844326a23650322810a0cb4ae82e3]

completion date [clinicaltrials_vocabulary:completion-date]

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

condition [clinicaltrials_vocabulary:condition]

Human Papillomavirus Infection [clinicaltrials_resource:464f7dab071bfeab8c3684793b845d29]

Vulvar Cancer [clinicaltrials_resource:742d1f4f459b0b7300863fe730bc02ac]

Cervical Cancer [clinicaltrials_resource:f11dcabf66eebfa24be0b52f213b79e2]

Vaginal Cancer [clinicaltrials_resource:f81b120d615f039ad9ccb9f162e67993]

Genital Warts [clinicaltrials_resource:f9707d6782b1085908b58bc8976f5670]

condition browse [clinicaltrials_vocabulary:condition-browse]

Uterine Cervical Neoplasms [clinicaltrials_resource:0dd545ed09b3355cb31844a8ed1369f6]

Vaginal Neoplasms [clinicaltrials_resource:306fc1369a4798c6985b04067b08b822]

Vulvar Neoplasms [clinicaltrials_resource:9700ce352a5c762c451e5df4bf382692]

Papillomavirus Infections [clinicaltrials_resource:e7646d8a181124843a18745b0c590f29]

condition mesh [clinicaltrials_vocabulary:condition-mesh]

Uterine Cervical Neoplasms [clinicaltrials_resource:0dd545ed09b3355cb31844a8ed1369f6]

Vaginal Neoplasms [clinicaltrials_resource:306fc1369a4798c6985b04067b08b822]

Vulvar Neoplasms [clinicaltrials_resource:9700ce352a5c762c451e5df4bf382692]

Papillomavirus Infections [clinicaltrials_resource:e7646d8a181124843a18745b0c590f29]

country [clinicaltrials_vocabulary:country]

United States [clinicaltrials_resource:f253efe302d32ab264a76e0ce65be769]

detailed description [clinicaltrials_vocabulary:detailed-description]

The study includes a do ...... of V503 (Extension Cohort 2).

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00543543 [clinicaltrials_resource:7f2c3f435eff9c3c4108e151a1705143]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2007-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

firstreceived results date [clinicaltrials_vocabulary:firstreceived-results-date]

2014-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Comparator: GARDASIL [clinicaltrials_resource:0e0adcb3f69261884edc28ca4a48b799]

Experimental: V503 [clinicaltrials_resource:c7574b3ff9cbbfd0ff0983c0ba6b2506]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-06-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Merck Sharp & Dohme Corp. [clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00543543

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

6

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Randomized, International, D ...... d to 16- to 26- Year-Old Women

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

V503-001

http://www.w3.org/2001/XMLSchema#string

outcome [clinicaltrials_vocabulary:outcome]

Base Study: Combined Incidence of HPV Type 31/33/45/52/58-related Disease (Test of Hypothesis) [clinicaltrials_resource:NCT00543543/outcome/1]

overall official [clinicaltrials_vocabulary:overall-official]

Medical Monitor [clinicaltrials_resource:27195d211abb9273c80c26c3f8388190]

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

participant flow [clinicaltrials_vocabulary:participant-flow]

participant flow for clinicaltrials:NCT00543543 [clinicaltrials_resource:7862a257a64d1ab4257d558137d465d1]

phase [clinicaltrials_vocabulary:phase]

Phase 3 [clinicaltrials_resource:8357418e2694434468870b487644532d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

reported events [clinicaltrials_vocabulary:reported-events]

Reported events for NCT00543543 [clinicaltrials_resource:9eddcb7b75706f0b71774c4d37e8099f]

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

2007_538

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

Merck Sharp & Dohme Corp. [clinicaltrials_resource:bd932dcb36d27f98f1bb6129a9c0d723]

start date [clinicaltrials_vocabulary:start-date]

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00543543 study design [clinicaltrials_resource:9d481964559453cb25f3be4cf739bb3a]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00543543

verification date [clinicaltrials_vocabulary:verification-date]

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00543543

http://www.w3.org/2001/XMLSchema#string